MétaCan
Menu
Back to cohort

S0847 Pregnancy Outcomes in the Tofacitinib Ulcerative Colitis OCTAVE Studies: An Update as of February 2020

2020· article· en· W3094593042 on OpenAlexaff
Uma Mahadevan, Daniel C. Baumgart, Marla C. Dubinsky, Jesús K. Yamamoto‐Furusho, Nervin Lawendy, Gauree G. Konijeti, Hans Peter Gröchenig, Thomas V. Jones, Nicole Kulisek, Kenneth Kwok, Chinyu Su

Bibliographic record

VenueThe American Journal of Gastroenterology · 2020
Typearticle
Languageen
FieldMedicine
TopicPregnancy and Medication Impact
Canadian institutionsUniversity of Alberta
Fundersnot available
KeywordsTofacitinibMedicinePregnancyPlaceboAdverse effectUlcerative colitisRandomized controlled trialAbortionMisoprostolObstetricsPediatricsInternal medicineDisease

Abstract

fetched live from OpenAlex

INTRODUCTION: Pregnant women with UC have a higher risk of adverse pregnancy outcomes compared with age-matched controls [1]. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. In rats and rabbits, tofacitinib exhibits teratogenic effects at 146 and 13 times, respectively, the human dose of 5 mg twice daily. There are no adequately sized, well-controlled studies of tofacitinib in pregnant women. METHODS: We report updated pregnancy outcomes [2] from 3 randomized, placebo-controlled studies (OCTAVE Induction 1&2: NCT01465763, NCT01458951; OCTAVE Sustain: NCT01458574) and an ongoing, open-label, long-term extension study (OCTAVE Open: NCT01470612) of tofacitinib in patients (pts) with moderately to severely active UC [3,4]. Pregnancy outcomes following maternal or paternal exposure to tofacitinib were identified from Pfizer’s internal safety database up to Feb 11, 2020, and categorized as healthy newborn, medical termination, fetal death, congenital malformation, spontaneous abortion, or lost to follow-up. Trial protocols required females of childbearing potential to use highly effective contraception, and included regular urine β-hCG testing. The study drug was discontinued in pts who became pregnant. RESULTS: The UC OCTAVE trials included 1,139 unique pts (including placebo), of whom 296 were females of childbearing age. A total of 34 pregnancies with exposure to tofacitinib were reported. Of these, 15 were cases of maternal exposure, all during the 1st trimester: 9 (60.0%) healthy newborns, 2 (13.3%) medical terminations, 2 (13.3%) spontaneous abortions, and 2 (13.3%) cases lost to follow-up. There were 19 cases of paternal exposure: 15 (78.9%) healthy newborns, 2 (10.5%) spontaneous abortions, and 2 (10.5%) cases lost to follow-up. There were no cases of fetal death or congenital malformation. CONCLUSION: The majority of known outcomes for both maternal and paternal cases were healthy newborns. Although there are limited data and follow-up available, this analysis was consistent with a previous analysis in pts with UC [2], as well as an analysis in pts with rheumatoid arthritis and psoriasis [5]. Tofacitinib should not be used during pregnancy unless clearly necessary.Table 1

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.012
metaresearch head score (Gemma)0.026
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.012
Threshold uncertainty score0.061

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0120.026
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0070.007
Science and technology studies0.0000.001
Scholarly communication0.0030.002
Open science0.0010.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0080.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.343
Teacher spread0.306 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations11
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of GastroenterologySame topicPregnancy and Medication ImpactFrench-language works237,207